US5206344A
(en)
*
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
CA1283046C
(en)
*
|
1986-05-29 |
1991-04-16 |
Nandini Katre |
Tumor necrosis factor formulation
|
US4745180A
(en)
*
|
1986-06-27 |
1988-05-17 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using heparin fragments
|
US5004605A
(en)
*
|
1987-12-10 |
1991-04-02 |
Cetus Corporation |
Low pH pharmaceutical compositions of recombinant β-interferon
|
US4847325A
(en)
*
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
IE62463B1
(en)
*
|
1988-07-07 |
1995-02-08 |
Res Dev Foundation |
Immunoconjugates for cancer diagnosis and therapy
|
US5091176A
(en)
*
|
1988-11-02 |
1992-02-25 |
W. R. Grace & Co.-Conn. |
Polymer-modified peptide drugs having enhanced biological and pharmacological activities
|
CA2006596C
(en)
*
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
WO1990015628A1
(en)
*
|
1989-06-14 |
1990-12-27 |
Cetus Corporation |
Polymer/antibiotic conjugate
|
FI920131A0
(fi)
*
|
1989-07-14 |
1992-01-13 |
Praxis Biolog Inc |
Cytokin- och hormonbaerare foer konjugatvaccin.
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
Method for the production of a human recombinant tumor necrosis factor inhibitor
|
JP2662311B2
(ja)
*
|
1989-08-07 |
1997-10-08 |
デビオファルム ソシエテ アノニム |
生物学的に活性な新規薬剤・ポリマー誘導体およびその製造方法
|
US5393735A
(en)
*
|
1990-08-09 |
1995-02-28 |
Rohm And Haas Company |
Herbicidal glutarimides
|
US5552391A
(en)
*
|
1990-01-16 |
1996-09-03 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
FR2658519B1
(fr)
*
|
1990-02-19 |
1995-07-07 |
Serbio |
Substrats peptidiques pour identification du facteur xa.
|
FR2658521B1
(fr)
*
|
1990-02-19 |
1994-01-21 |
Serbioo |
Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5312903A
(en)
*
|
1990-06-01 |
1994-05-17 |
E. I. Du Pont De Nemours And Company |
Lysine-glycosylated recombinant interleukin-2
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US5229366A
(en)
*
|
1990-10-23 |
1993-07-20 |
Fuji Photo Film Co., Ltd. |
Peptide-containing polyethylene glycol derivatives and application thereof
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
EP1808183A3
(en)
*
|
1993-09-08 |
2009-07-01 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5446090A
(en)
*
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
US5629384A
(en)
*
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
US20030053982A1
(en)
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US8071737B2
(en)
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
EP2168973A1
(en)
*
|
1995-05-04 |
2010-03-31 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
EP0850064A1
(en)
*
|
1995-09-14 |
1998-07-01 |
Lxr Biotechnology Inc. |
Compositions with anti-apoptotic activity, containing a mixture of phospholipids
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
CA2277757C
(en)
*
|
1997-01-15 |
2008-09-16 |
Phoenix Pharmacologics, Inc. |
Modified tumor necrosis factor
|
EP0973384A4
(en)
|
1997-02-13 |
2004-10-13 |
Sky High Llc |
ORGAN PRESERVATION SOLUTION
|
WO1999055377A2
(en)
*
|
1998-04-28 |
1999-11-04 |
Applied Research Systems Ars Holding N.V. |
Polyol-ifn-beta conjugates
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
PT2158923E
(pt)
|
1998-08-06 |
2013-06-04 |
Univ Duke |
Conjugados de peg-urato oxidase e sua utilização
|
AU766190B2
(en)
*
|
1998-10-16 |
2003-10-09 |
Biogen Idec Ma Inc. |
Interferon-beta fusion proteins and uses
|
NZ510689A
(en)
|
1998-10-16 |
2003-07-25 |
Biogen Inc |
Polymer conjugates of interferon beta-1a and uses
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6399578B1
(en)
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
US6458953B1
(en)
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
US7144574B2
(en)
|
1999-08-27 |
2006-12-05 |
Maxygen Aps |
Interferon β variants and conjugates
|
IL147581A0
(en)
*
|
1999-08-27 |
2002-08-14 |
Maxygen Aps |
New interferon beta-like molecules
|
US7431921B2
(en)
|
1999-08-27 |
2008-10-07 |
Maxygen Aps |
Interferon beta-like molecules
|
TR200101086A3
(instruction)
*
|
1999-10-15 |
2001-08-21 |
|
|
CN1309423C
(zh)
|
1999-11-12 |
2007-04-11 |
马克西根控股公司 |
干扰素γ偶联物
|
HRP20020387A2
(en)
|
1999-11-12 |
2005-10-31 |
Maxygen Holdings Ltd. |
Interferon gamma conjugates
|
AU782580B2
(en)
|
2000-01-10 |
2005-08-11 |
Maxygen, Inc. |
G-CSF conjugates
|
PT1257295E
(pt)
|
2000-02-11 |
2009-07-16 |
Bayer Healthcare Llc |
Moléculas de tipo factor vii ou viia
|
JP2003535208A
(ja)
|
2000-06-08 |
2003-11-25 |
ラ ホヤ ファーマシューティカル カンパニー |
高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
CA2469846A1
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
US7038015B2
(en)
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
WO2003000278A1
(fr)
*
|
2001-06-22 |
2003-01-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Onguents
|
CN1555268B
(zh)
|
2001-07-17 |
2013-04-03 |
研究发展基金会 |
含促调亡蛋白质的治疗剂
|
WO2003015697A2
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
CN1635901B
(zh)
|
2001-10-10 |
2012-03-28 |
诺和诺德公司 |
肽的重构和糖缀合的方法
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
AU2003210564B2
(en)
|
2002-01-18 |
2008-10-23 |
Biogen Ma Inc. |
Polyalkylene glycol with moiety for conjugating biologically active compound
|
RU2362807C2
(ru)
|
2002-06-21 |
2009-07-27 |
Ново Нордиск Хелт Кэр Аг |
Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция
|
US7524931B2
(en)
|
2002-07-03 |
2009-04-28 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
PT1667708E
(pt)
|
2002-12-26 |
2012-09-14 |
Mountain View Pharmaceuticals |
Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
EP2338333B1
(en)
|
2003-04-09 |
2017-09-06 |
ratiopharm GmbH |
Glycopegylation methods and proteins/peptides produced by the methods
|
EP1613261A4
(en)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
CN1910200A
(zh)
*
|
2003-08-07 |
2007-02-07 |
津莫吉尼蒂克斯公司 |
Il-28和il-29的均一化制剂
|
CN101880326B
(zh)
*
|
2003-08-25 |
2018-02-16 |
东丽株式会社 |
干扰素‑β复合物
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
EP1694347B1
(en)
|
2003-11-24 |
2013-11-20 |
BioGeneriX AG |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
EP1740608B1
(en)
|
2004-02-02 |
2012-02-22 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
ES2339953T5
(es)
|
2004-05-04 |
2020-05-06 |
Novo Nordisk Healthcare Ag |
Glicoformas de factor VII ligadas a O y método de fabricación
|
BRPI0512235A
(pt)
|
2004-06-18 |
2008-02-19 |
Ambrx Inc |
polipeptìdeos ligadores de antìgenos e seus usos
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
MX2007000728A
(es)
|
2004-07-21 |
2007-03-15 |
Ambrx Inc |
Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
NZ584597A
(en)
|
2004-12-22 |
2011-09-30 |
Ambrx Inc |
Modified human growth hormone
|
JP4951527B2
(ja)
|
2005-01-10 |
2012-06-13 |
バイオジェネリックス アーゲー |
糖peg化顆粒球コロニー刺激因子
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US8188224B2
(en)
|
2005-04-11 |
2012-05-29 |
Savient Pharmaceuticals, Inc. |
Variant forms of urate oxidase and use thereof
|
JP5335422B2
(ja)
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
US20090018029A1
(en)
|
2005-11-16 |
2009-01-15 |
Ambrx, Inc. |
Methods and Compositions Comprising Non-Natural Amino Acids
|
RU2322452C2
(ru)
*
|
2006-03-27 |
2008-04-20 |
Михаил Николаевич Смирнов |
Иммуномодулирующая композиция
|
RU2304586C1
(ru)
*
|
2006-03-27 |
2007-08-20 |
Михаил Николаевич Смирнов |
Препарат интерлейкина-2 и способ его получения
|
RU2008145084A
(ru)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
|
US20080242607A1
(en)
|
2006-07-21 |
2008-10-02 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
CN104193815A
(zh)
|
2006-09-08 |
2014-12-10 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
MX2009002820A
(es)
*
|
2006-09-15 |
2009-06-04 |
Creabilis Therapeutics Spa |
Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
DK2144923T3
(da)
|
2007-04-03 |
2013-05-13 |
Biogenerix Ag |
Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
|
CA2690611C
(en)
|
2007-06-12 |
2015-12-08 |
Novo Nordisk A/S |
Improved process for the production of nucleotide sugars
|
DK2197919T3
(da)
|
2007-08-27 |
2014-07-07 |
Ratiopharm Gmbh |
Flydende formulering af g-csf-konjugat
|
EP2217265B1
(en)
|
2007-11-20 |
2017-05-10 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
BRPI0905707B1
(pt)
*
|
2008-01-18 |
2024-02-27 |
Dow Global Technologies Inc |
Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
|
CN111346213A
(zh)
|
2008-01-22 |
2020-06-30 |
阿拉伊姆药品公司 |
用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
JP5619630B2
(ja)
|
2008-02-27 |
2014-11-05 |
ノボ・ノルデイスク・エー/エス |
結合型第viii因子分子
|
DK2279405T3
(da)
|
2008-05-13 |
2014-01-13 |
Advanced Liquid Logic Inc |
Dråbeaktuatorindretninger, -systemer og -fremgangsmåder
|
CA2729851C
(en)
|
2008-07-23 |
2019-01-15 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
WO2010036964A2
(en)
|
2008-09-26 |
2010-04-01 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
MX357314B
(es)
|
2008-09-26 |
2018-07-04 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
PL398781A1
(pl)
|
2009-06-25 |
2012-11-19 |
Savient Pharmaceuticals, Inc. |
Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
|
PH12012501252A1
(en)
|
2009-12-21 |
2012-11-05 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
WO2011107591A1
(en)
|
2010-03-05 |
2011-09-09 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
EP4302783A3
(en)
|
2010-08-17 |
2024-03-13 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
KR102349549B1
(ko)
|
2010-11-12 |
2022-01-11 |
넥타르 테라퓨틱스 |
Il-2 부분 및 중합체의 접합체
|
BR112013018932B1
(pt)
|
2011-02-10 |
2020-11-17 |
Roche Glycart Ag |
polipeptídeo de interleucina-2 (il-2) mutante, imunoconjugado, polinucleotídeo isolado, célula hospedeira de microrganismos, método de produção de um polipeptídeo de il-2 mutante, composição farmacêutica e usos do polipeptídeo de il-2 mutante ou do imunoconjugado
|
US9382305B2
(en)
|
2011-07-01 |
2016-07-05 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
CA2865879A1
(en)
|
2012-02-29 |
2013-09-06 |
Toray Industries, Inc. |
Inhibitory agent for body cavity fluid accumulation
|
GB201910190D0
(en)
|
2012-04-16 |
2019-08-28 |
Cantab Biopharmaceuticals Patents Ltd |
Optimised subsutaneous therapeutic agents
|
WO2013177187A2
(en)
*
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
WO2013185115A1
(en)
|
2012-06-08 |
2013-12-12 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
HRP20220455T1
(hr)
|
2012-08-31 |
2022-05-27 |
Sutro Biopharma, Inc. |
Modificirane aminokiseline koje sadrže azid grupu
|
US20150017120A1
(en)
*
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
ES2658039T3
(es)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
TWI705071B
(zh)
|
2014-10-24 |
2020-09-21 |
美商必治妥美雅史谷比公司 |
經修飾之fgf-21多肽及其用途
|
EP3359182B1
(en)
|
2015-10-08 |
2023-04-19 |
Nektar Therapeutics |
Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
|
WO2017189988A1
(en)
|
2016-04-29 |
2017-11-02 |
Araim Pharmaceuticals, Inc. |
Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
|
SG11201907209QA
(en)
|
2017-02-08 |
2019-09-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
LT3606946T
(lt)
|
2017-04-03 |
2022-10-25 |
F. Hoffmann-La Roche Ag |
Anti-pd-1 antikūno imunokonjugatai su mutantiniu il-2 arba su il-15
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
JP7275049B2
(ja)
*
|
2017-12-27 |
2023-05-17 |
協和キリン株式会社 |
Il-2改変体
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
US20220009986A1
(en)
|
2018-10-19 |
2022-01-13 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
US20220118050A1
(en)
|
2019-01-28 |
2022-04-21 |
Toray Industries, Inc. |
Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
|
JPWO2020158691A1
(ja)
|
2019-01-28 |
2021-12-02 |
東レ株式会社 |
肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
|
CN113660957B
(zh)
|
2019-02-12 |
2024-12-13 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
CN114051500A
(zh)
|
2019-07-02 |
2022-02-15 |
豪夫迈·罗氏有限公司 |
包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
|
IL293680B2
(en)
*
|
2019-12-13 |
2024-04-01 |
Synthekine Inc |
Il-2 orthologs and methods of use
|
CN115243726B
(zh)
|
2020-03-11 |
2025-07-15 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
JP2023521238A
(ja)
|
2020-04-15 |
2023-05-23 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫複合体
|
KR20230010240A
(ko)
|
2020-05-11 |
2023-01-18 |
에프. 호프만-라 로슈 아게 |
변형된 pbmc 및 면역접합체를 이용한 병용 요법
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
CN116635403A
(zh)
|
2020-12-04 |
2023-08-22 |
豪夫迈·罗氏有限公司 |
pH依赖性突变型白细胞介素-2多肽
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
CN118215674A
(zh)
|
2021-10-14 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
新颖白细胞介素-7免疫缀合物
|
JP2024537096A
(ja)
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
|
CN120548192A
(zh)
|
2023-01-20 |
2025-08-26 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|
US20250249093A1
(en)
|
2024-02-01 |
2025-08-07 |
Astrazeneca Ab |
Cytokine engagers and uses thereof
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|